Tag: plasma

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)

PyroGenesis Announces Second Quarter 2025 Results

MONTREAL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX:PYR) (OTCQX:PYRGF) (FRA:8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, today announces its financial and operating results for the second quarter ended June 30, 2025.

The U.S. Battery Circular Economy Advances with PNE’s South Carolina Flagship Recycling Facility

Company takes a major step to ensure a secure U.S. battery supply chain CHESTER, S.C., Aug. 6, 2025 /PRNewswire/ -- Princeton NuEnergy Inc. (PNE), a U.S....

Princeton NuEnergy receives NSF SuperBoost Grant to accelerate direct recycling of lithium-ion batteries

Princeton NuEnergy (PNE), an innovator in lithium-ion battery recycling, wins a SuperBoost grant from the NSF Energy Storage Engine in Upstate New York.

Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction

www.freyapharmasolutions.com

MDLifespan and Dr. Jill Carnahan Launch “Next Gen Mold Detox” Using Therapeutic Plasma Exchange

Dr Jill's MDLifespan Mold Protocol is the First Clinically Proven Therapeutic Plasma Exchange Detox to Remove up to 90% of Mold Toxins DENVER, Aug. 4,...

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

SHANGHAI, Aug. 1, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911,...

PyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes advanced all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, today announces that it will host a conference call at 12:00 PM Eastern Time on Thursday, August 7^th, 2025 to discuss the Company’s financial results for the second quarter 2025 which ended June, 30, 2025, as well as provide an update to the Company’s progress and other developments.

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of...

Hainan emerging as hub for export of digital content, culture

Manulife Asia Care Survey 2026: Independence as Asia’s New Legacy

Manulife Asia Care Survey 2026: Independence as Asia’s New Legacy

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

PyroGenesis Announces Second Quarter 2025 Results

The U.S. Battery Circular Economy Advances with PNE’s South Carolina Flagship Recycling Facility

Princeton NuEnergy receives NSF SuperBoost Grant to accelerate direct recycling of lithium-ion batteries

Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction

MDLifespan and Dr. Jill Carnahan Launch “Next Gen Mold Detox” Using Therapeutic Plasma Exchange

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

PyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

Fireweed Intersects Sulphide Mineralization at Boundary Zone Muon Targets

OncoHost Named Top Precision Oncology Solution for 2025

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Explore

Press Releases

News & Opinion

Living

Others

Follow us